Endocrine gland neoplasm

Researchers are testing a cell therapy made from healthy donor immune cells that are gene edited with CRISPR-Cas9 and engineered to target CD19, a marker on B-cell lymphomas. The trial enrolls about 30 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. Phase 1 chec…

Researchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…

Researchers are testing a new CAR-T cell therapy called C402-CD19-CAR in adults with large B-cell lymphoma that has come back or stopped responding to treatment. The therapy is made from each participant's own T cells, which are modified to target CD19, a marker on lymphoma cells…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This early-phase trial is testing an experimental therapy called DLL3-SAVVYZ-IL18 CAR T cells in people with advanced neuroendocrine cancers, including small cell lung cancer. The treatment involves reprogramming a patient's own immune cells to recognize and attack cancer cells t…

This trial is testing a high-dose radiation treatment called Yttrium-90 radioembolization for people with large hepatocellular carcinoma (a type of liver cancer) that is larger than 8 cm. The treatment delivers tiny radioactive beads directly to the tumor's blood supply, aiming t…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This phase 2 trial tests whether a combination of three treatments can shrink inoperable intrahepatic cholangiocarcinoma (a type of bile duct cancer) enough to allow surgical removal. The approach delivers chemotherapy directly into the liver's blood supply (HAIC) along with the …

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…

Researchers are testing tarlatamab in people with advanced extrapulmonary small cell carcinoma or neuroendocrine carcinoma that has worsened after platinum-based chemotherapy. These rare cancers often carry high levels of a protein called DLL3, which tarlatamab targets by linking…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

Researchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…

Researchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

Researchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study looks at whether adding radiation to the liver can improve outcomes for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that has spread. About 60 adults with at least one liver tumor 3 cm or larger will receive either standard therapy a…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

Researchers are testing sacituzumab govitecan, an antibody-drug conjugate, in adults with advanced differentiated or anaplastic thyroid cancer that has stopped responding to radioactive iodine. The drug targets TROP-2, a protein found at high levels on these cancer cells. The tri…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

Researchers compare two treatments for thyroid tumors smaller than 2 cm: standard surgery to remove half the thyroid gland, and radiofrequency ablation, which uses heat to destroy the tumor. The trial enrolls 88 people across multiple centers and follows them for five years. It m…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study tests whether adding a non-invasive sound wave treatment (histotripsy) to standard chemotherapy can help people with advanced colorectal cancer that has spread to the liver. About 100 adults whose cancer cannot be removed by surgery will receive both treatments. The go…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

Researchers are testing whether a balloon catheter coated with the drug sirolimus can safely open narrowed coronary arteries in adults with heart disease. The balloon inflates to press the drug into the artery wall, aiming to keep the vessel open without leaving a permanent stent…

This early-phase trial is testing whether combining an immunotherapy drug (nivolumab) with chemotherapy (fluorouracil) and an immune stimulant (interferon alpha 2b) can safely shrink or control fibrolamellar liver cancer that cannot be removed by surgery. The study will enroll 15…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

This early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…

Researchers are testing a new device that uses endoscopic ultrasound to guide microwave energy directly into pancreatic and liver tumors that cannot be removed by surgery. The study enrolls 75 adults with locally advanced or metastatic cancer. The main goal is to see whether the …

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This study tests a drug called sacituzumab govitecan in adults with advanced thymoma or thymic carcinoma that has worsened after at least one prior treatment. The main goal is to see how many patients' tumors shrink or disappear. Participants receive the drug intravenously weekly…

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack tumor cells, deliv…

This early-phase trial tests whether injecting a medical glue (Histoacryl®) into the pancreas during Whipple surgery can strengthen the connection between the pancreas and intestine and prevent dangerous leaks. The study involves 30 patients with soft pancreases and narrow ducts,…

This study tests a new drug, WGI-0301, combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery and has not responded to prior immunotherapy. The goal is to find the best dose and see if the combination can shrink tumors. Participants must…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

Researchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This study tests a device that uses nanosecond electrical pulses to destroy small papillary thyroid cancers (up to 1.5 cm) without cutting the skin. Fifteen participants will get the outpatient procedure under local anesthesia. The main goal is to check safety and side effects, n…

This study tests a new gene therapy (quaratusugene ozeplasmid) plus an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive stage small cell lung cancer. The goal is to see if the combination can keep the cancer from growing longer than standard ca…

This trial tests two chemotherapy strategies for people who have had surgery for malignant biliary tract tumors. One group receives hepatic arterial infusion chemotherapy, where drugs are delivered directly to the liver through a catheter. The other group takes capecitabine pills…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

Researchers are testing whether adding oral fecal microbiota transplantation capsules can help control advanced hepatocellular carcinoma that has worsened during treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The trial enrolls 30 adults with liver can…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

Neuroendocrine tumors often keep growing despite treatment with somatostatin analogues, drugs that slow tumor growth and reduce hormone production. When that happens, doctors add peptide receptor radionuclide therapy (PRRT), a targeted radiotherapy, but they do not know whether c…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study compares a new drug, zanzalintinib, to the current standard drug everolimus in people with advanced neuroendocrine tumors that have already been treated. The goal is to see which drug better slows tumor growth. About 440 participants will be randomly assigned to one of…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare …

This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the …

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-phase trial is testing whether giving a combination of two drugs (XL092 and cemiplimab) before surgery can help people with a rare and fast-growing thyroid cancer called anaplastic thyroid cancer. The study will enroll 12 participants to see if the treatment is safe an…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This phase II trial tests whether combining anlotinib, benmelstobart, and hepatic arterial infusion chemotherapy (HAIC) can shrink tumors in people with unresectable hepatocellular carcinoma, the most common type of liver cancer. The study enrolls adults aged 18 to 75 with confir…

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This trial tests whether tarlatamab, a drug that helps the immune system attack cancer cells, can improve survival in people with advanced small-cell lung cancer whose general health is poor. The study includes 57 participants who have already had at least one prior treatment. Re…

This phase 2 trial tests the drug zanzalintinib given before surgery in 45 people with advanced thyroid cancer. The goal is to see if the drug can shrink tumors, making surgery more effective. Researchers will also monitor safety and side effects.

This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two yea…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This trial compares two minimally invasive procedures, radiofrequency ablation (RFA) and microwave ablation (MWA), for treating large benign thyroid nodules. Adults with a single nodule of at least 20 milliliters will be randomly assigned to one of the two heat-based treatments. …

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests whether a team of specialists—including surgeons, oncologists, and geriatricians—can create better treatment plans for elderly lung cancer patients. 2,000 people aged 60-90 will receive personalized care based on their overall health and cancer type. The goal is …

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial tests whether combining an immunotherapy drug (iparomlimab/tuvonralimab), targeted radiation, and the drug lenvatinib can improve outcomes for people with intermediate-stage liver cancer that may be removable by surgery. Participants receive the combination bef…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This early-phase trial is testing whether combining two targeted therapies—sunitinib malate and Lutathera—is safe for people with advanced pancreatic neuroendocrine tumors that have spread or cannot be removed. Sunitinib blocks signals that help tumors grow, while Lutathera deliv…

This trial tests whether microwave ablation can shrink benign thyroid nodules more effectively than the standard radiofrequency ablation. Both methods use heat to destroy nodule tissue without surgery. The study enrolls adults with moderate-sized, mostly solid, benign nodules tha…

This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This trial tests whether adding a procedure called irreversible electroporation (IRE) to standard targeted immunotherapy can help people with unresectable liver cancer that has spread into the portal vein. About 60 adults who have already received three cycles of immunotherapy wi…

This study tests a drug called lurbinectedin in people aged 10 and older whose solid tumors (like Ewing sarcoma) have returned after standard treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic c…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …

This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow after at least one prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Docto…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage study tests a drug called codrituzumab in children and young adults (ages 1 to 21) whose solid tumors have come back or not responded to treatment and carry a specific protein called GPC3. The main goal is to find a safe dose and see how the body handles the drug…

This Phase 2 trial is testing two doses (20 mg and 16 mg) of the oral drug futibatinib in 120 people with advanced bile duct cancer that has specific FGFR2 gene changes. Participants must have already tried standard chemotherapy. The study aims to see which dose works better at s…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This trial tests whether adding an experimental drug called valemetostat to a standard two-drug therapy can help people with advanced liver cancer. The standard therapy combines atezolizumab and bevacizumab, which are already approved for this condition. The study includes adults…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This phase 2 trial tests a combination of liposomal irinotecan, fluorouracil, leucovorin, and sintilimab, followed by radiation therapy, as a first-line treatment for people with locally advanced biliary tract cancer that cannot be removed with surgery. About 31 participants will…

This trial tests whether giving patients their own activated T lymphocytes (ATL) after curative treatment for liver cancer can reduce the chance of the cancer coming back. The study enrolls adults with stage I, II, or IIIa hepatocellular carcinoma who have had or will have curati…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while …

This study tests a new medicine called Risvutatug rezetecan (Ris-Rez) that targets a specific protein (B7-H3) on cancer cells to stop their growth. It is for adults with relapsed small cell lung cancer who have already tried one prior treatment. About 420 participants will be ran…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This trial tests whether a technique called irreversible electroporation (IRE) can help people with a type of bile duct cancer that cannot be removed by surgery. IRE uses high-voltage electric pulses to create tiny holes in tumor cell membranes, causing the cells to die without t…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This trial is investigating whether giving a combination of chemotherapy and immunotherapy before surgery, and continuing immunotherapy after, can improve outcomes for people with a rare and aggressive type of bile duct cancer. Participants will be randomly assigned to receive ei…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This trial is testing a procedure called ablative radioembolization, which delivers tiny radioactive beads (Yttrium-90) directly to liver tumors. It is for adults with hepatocellular carcinoma that has spread into the portal vein but is still confined to one lobe of the liver. Th…

This trial tests a targeted radiation therapy for people with large, localized liver cancer that cannot be surgically removed. Tiny glass beads carrying Yttrium-90 are injected into the liver's blood vessels to deliver a high dose of radiation directly to tumors. Researchers will…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This trial tests a streamlined version of radioembolization, a treatment that delivers tiny radioactive beads directly to liver tumors. The standard procedure requires extra imaging beforehand to check for radiation leakage to the lungs, which can delay treatment. For patients wi…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This trial is testing whether a pill form of the chemotherapy drug paclitaxel, taken alongside an immune checkpoint inhibitor, can help people with advanced lung cancer stay stable longer after their first round of treatment. The study includes two groups: one with squamous non-s…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This trial tests whether a procedure called underwater endoscopic mucosal resection (UEMR) can safely and completely remove small type I gastric neuroendocrine tumors (5-9 mm). Instead of traditional surgery, doctors fill the stomach with saline and use a snare to cut out the gro…

This study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…

This phase 3 trial tests whether a combination of two experimental drugs (futibatinib and zimberelimab) plus standard chemotherapy can help people with advanced biliary tract cancer live longer compared to current standard immunotherapy combinations. The study enrolls about 784 a…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the…

This study tests a shorter, higher-dose-per-day radiation schedule (hypofractionated radiotherapy) given after complete surgical removal of stage II or III thymic epithelial tumors. The goal is to see if this approach is safe and tolerable, while also checking how well it control…

This study tests whether combining two drugs, atezolizumab and bevacizumab, given before and after surgery can help prevent liver cancer from coming back. It enrolls adults with a type of liver cancer that can be surgically removed but has a high risk of recurrence. Participants …

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This trial investigates a new cell therapy called ET140203 T cells for children and young adults (ages 1–21) with certain liver cancers—hepatoblastoma, hepatocellular carcinoma, or related tumors—that have come back or not responded to standard treatment. Participants must have h…

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to s…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests whether using heat (radiofrequency ablation) to destroy cancer tissue inside the bile duct before placing a metal stent can keep the duct open longer than placing a stent alone. It involves 122 adults with inoperable bile duct cancer. The main goal is to see how …

Researchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…

This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…

Researchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study tests a new PET scan using a special form of iodine called iodine-124 to measure how much radioactive iodine thyroid cancer tumors absorb. The goal is to help doctors decide if standard radioactive iodine therapy is likely to help. About 60 adults with metastatic thyro…

Researchers are testing a new PET/CT imaging tracer designed to spot insulinomas, rare pancreatic tumors that cause dangerously low blood sugar. These tumors are often tiny and easy to miss on standard CT, ultrasound, or PET scans. The tracer targets a protein called GLP-1R that …

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked. Researchers will compare the new CEUS criteria with standard CT or MRI scans in 200 adults. If accurate, this could make follow-up safer and easier by avoidin…

This trial tests whether a single injection of a radioactive tracer called 68Ga/18F-Exendin 4 can improve PET/CT scans for finding tumors that carry GLP-1 receptors. Researchers will enroll 500 adults with suspected or known tumors, including insulinomas, and measure how brightly…

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

This study is testing a new, single-use scope called the Dragonfly™ Digital Pancreaticobiliary System. It is designed to help doctors see inside the bile and pancreatic ducts during an endoscopy. The study will enroll up to 75 adults with bile duct stones or narrowings (stricture…

This study tests a special PET/CT scan using a radioactive tracer called PSMA to get clearer images of liver cancer (HCC). Researchers want to see if this dynamic whole-body scan can better detect new or returning tumors compared to standard methods. Forty adults with liver cance…

This trial tests a new radioactive tracer called 18F-X12 for PET/CT imaging in people with suspected or confirmed hepatocellular carcinoma, the most common type of liver cancer. The goal is to see if this tracer can accurately detect and stage tumors, and help spot recurrences af…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study aims to improve how doctors diagnose Cushing's syndrome, a condition caused by too much cortisol. Researchers will test the accuracy of the desmopressin stimulation test in 140 people aged 18-70 who have or may have Cushing's, plus healthy volunteers. Participants will…

This study explores whether a common blood test that measures how well blood clots (called TEG) can also act as a biomarker for cancer. Researchers will compare TEG results from patients with several types of cancer (liver, pancreas, bile duct, esophagus, colorectal, and lung) ag…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…

This pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is t…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This study is testing a new blood test designed to detect liver cancer (hepatocellular carcinoma) early in people who are at high risk because they have cirrhosis. The test looks for specific DNA markers and proteins in the blood that may signal the presence of cancer. Researcher…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

Researchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tracks 50 people who choose radiofrequency ablation (RFA) for benign thyroid nodules or low-risk papillary thyroid cancer instead of surgery. Researchers will monitor long-term outcomes and quality of life using questionnaires. The goal is to see if RFA is a good alter…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

Researchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…

This phase II trial tests whether a standardized acupuncture protocol can reduce peripheral neuropathy, a common and often lasting side effect of oxaliplatin chemotherapy. Participants are adults with gastrointestinal solid tumors who stopped oxaliplatin-based treatment and still…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests whether a WeChat mini program that guides neck rehabilitation exercises can help people recover more comfortably after thyroid surgery. About 200 adults who have had their thyroid removed will either use the app-based program or receive standard care with video i…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers sug…

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This study compares two types of nerve blocks (retrolaminar block vs subcostal TAP block) to control pain after open liver surgery for cancer. The goal is to see which block reduces the need for strong painkillers (opioids) and helps patients recover faster. About 90 adults under…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether a mobile app called THRIVE can help people with newly diagnosed advanced lung cancer feel better day-to-day. Researchers will compare quality of life, physical and emotional symptoms, and coping skills between app users and those receiving usual care. The…

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study is testing whether giving patients unlimited access to a secure website with an explanatory video about thyroid surgery can lower their anxiety before the operation. About 220 adults scheduled for thyroid surgery will take part. Researchers will measure anxiety using s…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study compares a newer, less invasive endoscopic procedure to standard surgery for treating gastric outlet obstruction, a blockage that prevents food from leaving the stomach. The trial will enroll 32 adults with advanced cancers causing this blockage. The main goal is to se…

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study observes adults with advanced thyroid cancer who are receiving standard treatments in real-world settings, not in clinical trials. Researchers aim to understand barriers to accessing care and how well patients tolerate and respond to available medications. About 459 pa…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study follows up to 3,000 people who have, are at risk for, or are related to someone with a parathyroid disorder. Researchers will collect medical records, questionnaires, and samples like blood and saliva to learn what causes these conditions and how they change over time.…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…

This study follows up to 2,500 people with thyroid problems like hyperthyroidism, hypothyroidism, or Graves' disease. Researchers will track how these conditions develop over time using standard medical tests and genetic samples. The goal is to better understand the natural histo…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …

This study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…

This study aims to find the genetic causes of primary aldosteronism, a condition where adrenal tumors cause high blood pressure, in Black individuals. Researchers will enroll 1150 participants, including those with difficult-to-control blood pressure or known primary aldosteronis…

This study aims to improve how doctors find and understand pheochromocytomas and paragangliomas, rare tumors that can cause dangerous high blood pressure. Researchers will use advanced imaging scans and genetic testing in up to 3,000 participants to learn more about these tumors.…

This study aims to better understand why some people experience dangerously low blood sugar (hypoglycemia), especially after fasting. Researchers will admit 1,500 adults to the NIH Clinical Center for controlled fasting and a series of blood tests to measure insulin and other fac…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study tests a new imaging method called qDSA that measures blood flow in real time during liver embolization, a procedure that blocks blood supply to tumors. Up to 20 participants will have qDSA and ultrasound images taken before, during, and after the procedure. The goal is…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study is creating a registry of 750 people with a rare and aggressive form of cervical cancer called neuroendocrine carcinoma. Researchers will collect information from medical records to learn more about the disease, how it is treated, and what happens to patients over time…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

This study looks at whether a thorough health assessment before liver surgery can help older patients (70+) have fewer serious complications and recover better. Researchers will give 242 participants a special geriatric evaluation that checks frailty, memory, nutrition, and daily…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …

This study tests two ways of preparing people with advanced thyroid cancer for a special PET scan that uses a radioactive form of iodine (I-124). The goal is to see which preparation method gives better information for calculating the right dose of radiation therapy. Thirty parti…

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…

This study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

Researchers at IRCCS San Raffaele are creating a registry of images and videos from endoscopic ultrasound procedures performed to investigate pancreatic diseases. The study will gather data from about 12,000 patients with conditions like pancreatitis, pancreatic cancer, and neuro…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study looks at families where non-medullary thyroid cancer runs in the family. Researchers want to learn how the disease develops, find genes that might increase risk, and figure out the best way to screen for it early. Participants will have exams, imaging, and blood tests,…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This pilot study will test a new ultrasound probe and machine learning software to see if they can better visualize thyroid nodules compared to standard ultrasound. About 30 adults with known benign thyroid nodules will receive both types of scans. The goal is to improve detectio…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study tests whether a special catheter called TriNav can deliver more radiation beads (Y90 microspheres) to liver tumors while reducing exposure to healthy liver tissue. Twenty adults with unresectable liver tumors will receive the standard radioembolization procedure using …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study is for people who have or might have a thyroid nodule or thyroid cancer. Researchers want to learn more about how to diagnose and treat these conditions. Participants will have standard medical tests like blood draws and scans, plus some extra research tests. The goal …

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study is looking at why some people with advanced cancer lose weight and muscle, a condition called cachexia. Researchers will follow 800 patients with advanced lung, pancreatic, or colorectal cancer to see if there are distinct subtypes of cachexia based on symptoms, biomar…

This study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study looks at how often thyroid cancer is found by accident when people with Graves' disease have their thyroid gland removed. Researchers will track 280 adults having this surgery and examine the removed tissue carefully for any cancer, including tiny microcarcinomas. They…

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This study follows 150 adults with liver or bile duct cancer who are receiving standard treatments like surgery, ablation, or chemotherapy. Researchers will collect repeated blood samples before, during, and after treatment to analyze tumor DNA, immune cells, and proteins. The go…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five…

This European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, …

This study investigates whether exposure to certain chemicals found in the environment, home, or workplace can increase the risk of developing paraganglioma tumors in people who carry an inherited SDHx gene mutation. Researchers will compare chemical exposure histories between mu…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resis…

This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …

This study adds a heart-focused PET scan to a standard cancer imaging test (Gallium-68-DOTATOC) in 99 adults with neuroendocrine tumors. The goal is to see if the scan can detect heart inflammation linked to age and cardiovascular risk factors. Researchers will also compare scan …

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is collecting blood, urine, and stool samples from 300 people with cirrhosis to build a biobank. Researchers will later use these samples to understand how factors like nutrition, physical activity, smoking, alcohol, and pollution influence the development of the most …

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid givi…

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …